Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments.
Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments.
复制标题
DOI：
10.1016/j.canlet.2013.11.015
复制
发表时间：
2014-04-01
期刊：
影响因子：
9.7
通讯作者：
Ferrari, Mauro
中科院分区：
文献类型：
--
作者：
Yokoi, Kenji;Tanei, Tomonori;Godin, Biana;van de Ven, Anne L.;Hanibuchi, Masaki;Matsunoki, Aika;Alexander, Jenolyn;Ferrari, Mauro
增强渗透和保留（EPR）效应，即纳米治疗药物在肿瘤中积累的机制，因肿瘤和器官微环境的差异而在患者中有所不同。EPR效应的替代生物标志物将有助于选择积累更多纳米治疗药物并显示更好治疗效果的患者。我们的数据表明，血管通透性和聚乙二醇化脂质体（PLD）积累的差异是肿瘤类型和器官特异性的，并与循环中MMP-9与TIMP-1的相对比例显著相关，这支持了这些分子作为个性化纳米颗粒治疗的生物标志物的发展。
Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy.
登录
查看更多内容
影响因子：
50.5
作者：
O'Brien, MER;Wigler, N;Tendler, C
通讯作者：
Tendler, C
影响因子：
17.1
作者：
Ren Y;Cheung HW;von Maltzhan G;Agrawal A;Cowley GS;Weir BA;Boehm JS;Tamayo P;Karst AM;Liu JF;Hirsch MS;Mesirov JP;Drapkin R;Root DE;Lo J;Fogal V;Ruoslahti E;Hahn WC;Bhatia SN
通讯作者：
Bhatia SN
影响因子：
3.1
作者：
Malemud, CJ
通讯作者：
Malemud, CJ
影响因子：
78.8
作者：
Jain, Rakesh K.;Stylianopoulos, Triantafyllos
通讯作者：
Stylianopoulos, Triantafyllos
影响因子：
10.8
作者：
Maeda, H;Wu, J;Hori, K
通讯作者：
Hori, K